Cargando…

Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran

BACKGROUND: Concerns about the side effects of SARS-CoV-2 vaccines have been raised nationwide. We aimed to compare the time to report the side effects of the Oxford-AstraZeneca and Sinopharm COVID-19 vaccines. METHODS: Information on side effects of AstraZeneca and Sinopharm COVID-19 vaccines was o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zare, Marjan, Mirahmadizadeh, Alireza, Khosravi, Masoumeh, Karimi, Mohammadreza, Dehghani, Seyedeh Leila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iran University of Medical Sciences 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657253/
https://www.ncbi.nlm.nih.gov/pubmed/38021386
http://dx.doi.org/10.47176/mjiri.37.99
_version_ 1785137175777509376
author Zare, Marjan
Mirahmadizadeh, Alireza
Khosravi, Masoumeh
Karimi, Mohammadreza
Dehghani, Seyedeh Leila
author_facet Zare, Marjan
Mirahmadizadeh, Alireza
Khosravi, Masoumeh
Karimi, Mohammadreza
Dehghani, Seyedeh Leila
author_sort Zare, Marjan
collection PubMed
description BACKGROUND: Concerns about the side effects of SARS-CoV-2 vaccines have been raised nationwide. We aimed to compare the time to report the side effects of the Oxford-AstraZeneca and Sinopharm COVID-19 vaccines. METHODS: Information on side effects of AstraZeneca and Sinopharm COVID-19 vaccines was obtained from the COVID-19 Symptom Study App affiliated with Shiraz University of Medical Science during 2021. A COX regression model with an adjusted Hazard Ratio and 95% Confidence Interval; HR (95% C.I) was reported at the significance level of < 0.05. RESULTS: 4478 and 5555 participants received the AstraZeneca and Sinopharm vaccines, respectively; more age, history of SARS-CoV-2 infection, first vaccine dose, hypertension, and hypertension with cardiovascular disease were seen in the AstraZeneca group (P < 0.05 for all). However, the AstraZeneca group had lower immune deficiency and time to report the side effects (P < 0.05 for both). There was significantly less time to pain HR(95% C.I.); 0.50 (0.47-0.52), vertigo 0.65 (0.61-0.69), weakness 0.41 (0.38-0.44), headache 0.43 (0.39-0.74), anorexia 0.31 (0.28-0.34), nausea 0.56 (0.51-0.62), severer allergy 0.71 (0.63-0.81), general inflammation 0.27 (0.23-0.31), fever > 38oC 0.12 (0.1-0.15), eye inflammation 0.45 (0.39-0.52), diarrhea 0.85 (0.73-0.99), blurred vision 0.73 (0.61-0.86), injection site redness 0.32 (0.26-0.39), fatigue/paleness 0.53 (0.50-0.57), joint pain 0.55 (0.41-0.73), auxiliary gland inflation 0.59 (0.43-0.80), convulsions 0.30 (0.17-0.52), and severe side effects 0.3 (0.27-0.33) in the AstraZeneca group; However, skin rash 0.77 (0.57-1.05) and hospitalization 0.72 (0.21-2.55) were the same. CONCLUSION: Sinopharm COVID-19 vaccine recipients reported longer times to report vaccine-related side effects than AstraZeneca; due to the lack of adverse effects like hospitalization, vaccination should continue to control the pandemic; more real-population studies are needed on the long-term effects of vaccination against COVID-19.
format Online
Article
Text
id pubmed-10657253
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Iran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-106572532023-09-12 Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran Zare, Marjan Mirahmadizadeh, Alireza Khosravi, Masoumeh Karimi, Mohammadreza Dehghani, Seyedeh Leila Med J Islam Repub Iran Original Article BACKGROUND: Concerns about the side effects of SARS-CoV-2 vaccines have been raised nationwide. We aimed to compare the time to report the side effects of the Oxford-AstraZeneca and Sinopharm COVID-19 vaccines. METHODS: Information on side effects of AstraZeneca and Sinopharm COVID-19 vaccines was obtained from the COVID-19 Symptom Study App affiliated with Shiraz University of Medical Science during 2021. A COX regression model with an adjusted Hazard Ratio and 95% Confidence Interval; HR (95% C.I) was reported at the significance level of < 0.05. RESULTS: 4478 and 5555 participants received the AstraZeneca and Sinopharm vaccines, respectively; more age, history of SARS-CoV-2 infection, first vaccine dose, hypertension, and hypertension with cardiovascular disease were seen in the AstraZeneca group (P < 0.05 for all). However, the AstraZeneca group had lower immune deficiency and time to report the side effects (P < 0.05 for both). There was significantly less time to pain HR(95% C.I.); 0.50 (0.47-0.52), vertigo 0.65 (0.61-0.69), weakness 0.41 (0.38-0.44), headache 0.43 (0.39-0.74), anorexia 0.31 (0.28-0.34), nausea 0.56 (0.51-0.62), severer allergy 0.71 (0.63-0.81), general inflammation 0.27 (0.23-0.31), fever > 38oC 0.12 (0.1-0.15), eye inflammation 0.45 (0.39-0.52), diarrhea 0.85 (0.73-0.99), blurred vision 0.73 (0.61-0.86), injection site redness 0.32 (0.26-0.39), fatigue/paleness 0.53 (0.50-0.57), joint pain 0.55 (0.41-0.73), auxiliary gland inflation 0.59 (0.43-0.80), convulsions 0.30 (0.17-0.52), and severe side effects 0.3 (0.27-0.33) in the AstraZeneca group; However, skin rash 0.77 (0.57-1.05) and hospitalization 0.72 (0.21-2.55) were the same. CONCLUSION: Sinopharm COVID-19 vaccine recipients reported longer times to report vaccine-related side effects than AstraZeneca; due to the lack of adverse effects like hospitalization, vaccination should continue to control the pandemic; more real-population studies are needed on the long-term effects of vaccination against COVID-19. Iran University of Medical Sciences 2023-09-12 /pmc/articles/PMC10657253/ /pubmed/38021386 http://dx.doi.org/10.47176/mjiri.37.99 Text en © 2023 Iran University of Medical Sciences https://creativecommons.org/licenses/by-nc-sa/1.0/This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial-ShareAlike 1.0 License (CC BY-NC-SA 1.0), which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Original Article
Zare, Marjan
Mirahmadizadeh, Alireza
Khosravi, Masoumeh
Karimi, Mohammadreza
Dehghani, Seyedeh Leila
Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran
title Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran
title_full Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran
title_fullStr Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran
title_full_unstemmed Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran
title_short Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran
title_sort comparison of time to report the side effects after astrazeneca and sinopharm vaccinations in users of the covid-19 symptom study app: a survey in south iran
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657253/
https://www.ncbi.nlm.nih.gov/pubmed/38021386
http://dx.doi.org/10.47176/mjiri.37.99
work_keys_str_mv AT zaremarjan comparisonoftimetoreportthesideeffectsafterastrazenecaandsinopharmvaccinationsinusersofthecovid19symptomstudyappasurveyinsouthiran
AT mirahmadizadehalireza comparisonoftimetoreportthesideeffectsafterastrazenecaandsinopharmvaccinationsinusersofthecovid19symptomstudyappasurveyinsouthiran
AT khosravimasoumeh comparisonoftimetoreportthesideeffectsafterastrazenecaandsinopharmvaccinationsinusersofthecovid19symptomstudyappasurveyinsouthiran
AT karimimohammadreza comparisonoftimetoreportthesideeffectsafterastrazenecaandsinopharmvaccinationsinusersofthecovid19symptomstudyappasurveyinsouthiran
AT dehghaniseyedehleila comparisonoftimetoreportthesideeffectsafterastrazenecaandsinopharmvaccinationsinusersofthecovid19symptomstudyappasurveyinsouthiran